Ontology highlight
ABSTRACT:
SUBMITTER: Sosman JA
PROVIDER: S-EPMC3724515 | biostudies-literature | 2012 Feb
REPOSITORIES: biostudies-literature
Sosman Jeffrey A JA Kim Kevin B KB Schuchter Lynn L Gonzalez Rene R Pavlick Anna C AC Weber Jeffrey S JS McArthur Grant A GA Hutson Thomas E TE Moschos Stergios J SJ Flaherty Keith T KT Hersey Peter P Kefford Richard R Lawrence Donald D Puzanov Igor I Lewis Karl D KD Amaravadi Ravi K RK Chmielowski Bartosz B Lawrence H Jeffrey HJ Shyr Yu Y Ye Fei F Li Jiang J Nolop Keith B KB Lee Richard J RJ Joe Andrew K AK Ribas Antoni A
The New England journal of medicine 20120201 8
<h4>Background</h4>Approximately 50% of melanomas harbor activating (V600) mutations in the serine-threonine protein kinase B-RAF (BRAF). The oral BRAF inhibitor vemurafenib (PLX4032) frequently produced tumor regressions in patients with BRAF V600-mutant metastatic melanoma in a phase 1 trial and improved overall survival in a phase 3 trial.<h4>Methods</h4>We designed a multicenter phase 2 trial of vemurafenib in patients with previously treated BRAF V600-mutant metastatic melanoma to investiga ...[more]